Source: Annual Congress 2012 - Lung injury and repair: reactive oxygen species and beyond
Disease area: Airway diseases

Abstract

Background. Chronic obstructive pulmonary diseases are diagnosed in 4-6 % of men and 1-3 %
of women above 40 years old. The persistent inflammatory process in bronchi, the development of
microcirculation disorders, the increasing of hypoxia processes result in the activation of fibroblasts
and their production of IV-type collagen, which is manifested by the formation of peribronchial
pneumosclerosis.
Purpose of the study: the evaluation of the IV-type collagen level dynamics in BALF of patients with 3rd
stage COPD during the treatment with Roflumilast.
Materials and methods: The contents of the IV-type collagen in BALF was evaluated in 39 patients with III stage COPD in a relapse stage using enzyme-linked immunosorbent assay before and after 3 months of treatment with the inhibitor of phosphodiesterase -4 – Roflumilast, 500 mg per day, inside, together with the basic 3rd stage COPD treatment (GOLD, 2010).
Results of the study: The contents of the IV-type collagen in BALF before the beginning of treatment in
patients with 3rd stage COPD was (69.13±3.12) ng / ml, which is in 7,14 times higher than in almost healthy people,
whose contents constituted (9,68±0,54) ng / ml. After the second examination in 90 days, the above –
mentioned indicator in patients fell down by 2,45 times and was equal (28,26±2,23) ng / ml.
Conclusions: The depression of IV-type collagen levels demonstrate the ability to slow down pneumosclerosis progression in patients with III COPD who are treated with Roflumilast.

Rating:

Share or cite this content

Citations should be made in the following way:
M. Ostrovskyy, O. Varunkiv, I. Savelikhina, M. Kulynych-Miskiv (Ivano-Frankivsk, Ukraine). The influence of roflumilast on the IV-type collagen level in patients with III stage COPD. Eur Respir J 2012; 40: Suppl. 56, 3775

Member's Comments

No comment yet.

Related content which might interest you: Effects of tiotropium on lung volumes during exercise in GOLD stage II to IV COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 171s Year: 2006 Collagen I, III and IV content in airways and lung parenchyma of COPD patients Source: Annual Congress 2010 - Proteases and the matrix Year: 2010 Comorbidities in stage IV COPD patients Source: Annual Congress 2011 - COPD management Year: 2011 C-reactive protein and the type IV collagen measurementin severe COPD: Value of roflumilast Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 The role of determining the levels of collagen type IV in the management of patients with severe chronic obstructive pulmonary disease – Focus on roflumilast Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Type XIX collagen quantified in serum targeting the anti-tumorigenic NC1 domain is elevated in early and late stage lung carcinoma patients and COPD Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Dynamics of marker of inflammation - sICAM-1 in the process of treatment of COPD GOLD III destabilization phase in overweight patients. Source: Virtual Congress 2021 – Environmental and lifestyle impacts on chronic lung disease Year: 2021 The use of symbicort in the treatment of patients with I and II stages of pulmonary sarcoidosis Source: Eur Respir J 2007; 30: Suppl. 51, 85s Year: 2007 Collagen degradation profile in serum of patients with COPD or IPF Source: Annual Congress 2012 - Monitoring of airway diseases: far from the airways Year: 2012 Effects of pulmonary rehabilitation on peripheral muscle fibre characteristics in COPD patients with gold stages II to IV Source: Annual Congress 2009 - Emerging physiology behind pulmonary rehabilitation Year: 2009 The lung deposition of tiotropium in COPD patients is comparable to that in healthy subjects and independent of the stage of COPD disease Source: Eur Respir J 2003; 22: Suppl. 45, 51s Year: 2003 Polymorphisms in the type IV collagen alpha3 gene and the risk of COPD Source: Eur Respir J 2008; 32: 35-41 Year: 2008 Physician-diagnosed COPD GOLD stage IV in Östersund, Sweden: prevalence and patient characteristics Source: Eur Respir J 2006; 28: Suppl. 50, 447s Year: 2006 The prevalence of QTc-prolongation increase by GOLD stage in COPD Source: International Congress 2017 – Prevalence, prognosis and comorbidities of COPD and factors associated with lung function Year: 2017 Extended analysis of phase III trial of pirfenidone: More pronounced effect in mild impairment of patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 NSCLC stage IV Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 The use fluimucil (N-acetylcysteine) in the treatment in patients with III and IY stages of pulmonary sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 713s Year: 2004 Effect of COPD severity on hemodynamic responses to exercise in patients with GOLD stages I-IV Source: Annual Congress 2011 - Exercise tests and emerging outcomes: defining the impact of pulmonary rehabilitation Year: 2011 Serum levels of a MMP-12 generated type IV collagen fragment is elevated in COPD and IPF patients Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 Fatigue in patients with idiopathic pulmonary fibrosis (IPF) from the pooled pirfenidone (PFD) Phase III trials Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017